Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829920 · ClinicalTrials.gov registry record
The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 44
- Enrollment target
NCT00829920 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 44 participants.
The verdict
NCT00829920 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
Study Summary
The investigators hypothesize that circulating tumor cells (CTC) will be observed in patients with muscle-invasive or metastatic bladder cancer and that CTC will become undetectable, at least transiently, in a fraction of patients after treatment. To investigate this hypothesis, investigators will assess the levels of CTCs both before and after treatment. The feasibility and potential value of fluorescent in situ hybridization (FISH) in the CTCs will be assessed.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2008-11 |
| Est. Completion | 2013-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00829920
The ClinicalTrials.gov registry entry for NCT00829920 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00829920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00829920 about?
NCT00829920 is a clinical study titled "The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease". The investigators hypothesize that circulating tumor cells (CTC) will be observed in patients with muscle-invasive or metastatic bladder cancer and that CTC will become undetectable, at least transiently, in a fraction of patients after treatment. To investigate this hypothesis, investigators will a...
What is the current status of trial NCT00829920?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2008-11. Estimated completion is 2013-02.
Who is sponsoring clinical trial NCT00829920?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.